TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06290934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1427
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1427
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1427
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1427
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-to-match GS-1427
Description: Administered orally
Study: NCT05750654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Small Phlebotomy Tube Group
Description: In the small tubes group, the recommended blood volumes are 0.5 mL for hematology and single chemistry tests, and 1 mL when multiple chemistry tests are needed. A, a non-formulary medication order will be placed in the electronic medical record to alert nurses to collect blood in small tubes. Participants will continue to use small tubes anytime they are in the ICU or IMU.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Phlebotomy Tube Group
Description: In the standard tubes group, the recommended blood volumes are 4.0 mL for hematology and 3.0 for chemistry tests.
Study: NCT04271436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Description: A single dose of 10 mCi FDG will be given by bolus injection approximately 60 minutes prior to the first planned imaging procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLT PET/CT
Description: . A single dose of 10 mCi FLT will be given by bolus injection approximately 80 minutes prior to the first planned imaging procedure.
Study: NCT05258890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Network Group Counseling
Description: Researchers will identify the influential network members based on their network position, driving distance from the patient, speaking frequency, and whether they have high blood pressure. The index patient and social network members will meet with the study nurse on weeks 2, 6, and 12 after initial enrollment. The study nurse will begin the social network counseling session in which she will provide counseling on teamwork and blood pressure control. The teamwork specific topics will include how networks can work together as a team, communication tips for engaging with one another, spreading positive messages, and establishing the roles and responsibilities of each network team member. The blood pressure control specific topics will include the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. Patient and social network members will receive text messages every week in the weeks between sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Counseling
Description: The index patient will meet individually with the study nurse on weeks 2, 6, and 12 after initial enrollment. The nurse will provide counseling on the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. The patient will receive text messages every week in the weeks between sessions.
Study: NCT04311996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
Study: NCT04271436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: MR imaging will be performed on a Siemens Biograph mMR or an MRI scanner, if the PET/MR is unavailable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18] flurothymidine
Description: -Radiopharmaceutical
Study: NCT06539858

Intervention type: OTHER
Intervention: massage
Description: General back massage from the base of the neck to the sacrum. Classical massage techniques such as stroking and kneeding will be applied. To be performed by a specialist physiotherapist.
Study: NCT06276881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Stimulation
Description: AI-guided visual stimuli presented on an electronic screen
Study: NCT05564884

Intervention type: OTHER
Intervention: no intervantion
Description: no intervention

Intervention type: OTHER
Intervention: no intervantion
Description: no intervention

Intervention type: OTHER
Intervention: no intervantion
Description: no intervention
Study: NCT06478797

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid
Description: Sepsis will be treated with standardized therapy protocol, where participants receive fluids (balanced or non-balanced crystalloids, or colloids) to be resuscitated. Specifically, they will receive 40-60 ml/kg of fluids before the initiation of inotropes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenalin
Description: Sepsis will be treated with early inotropes, where participants will receive adrenaline at a dose of 0.05 - 0.1 mcg/kg/min via peripheral intravenous, intraosseous, or central venous routes after the first fluid bolus of 20 ml/kg
Study: NCT05023616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time home CPR training
Description: The participants in the intervention group will have Little Anne QCPR mannequins (Laerdal, Stavanger, Norway) delivered to their homes. The participants will use an online platform specifically developed for CPR training (HEROS Remote app). The training program will provide video-based self-instruction training followed by hands-on chest compression training with the instructor. The hands-on chest compression training session provides real-time chest compression quality measurement followed by real-time feedback from the instructor. Chest compression quality will be measured by Little Anne QCPR mannequins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CPR training
Description: Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequins will be provided to measure and give feedback on the participants chest compression performance.
Study: NCT05375539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-CognI.Q
Description: Herbal dietary supplement products containing/based on AGN alcoholic extracts (including CognI.Q; Decursinol-50TM, GWB78®, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) are marketed in the US for memory enhancement, pain relief and for women's post-menopausal symptom management.
Study: NCT05948670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISC-MVP
Description: DISC-MVP is a digital program grounded in validated psychotherapies (e.g., cognitive behavioral therapy), that enlists a relational agent (Woebot) to engage users in therapeutic conversations and generates responses through a controlled process using large language models.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DISC-CON
Description: DISC-CON is a digital program grounded in validated psychotherapies (e.g., including cognitive behavioral therapy) that uses a virtual relational agent (Woebot) to engage users in therapeutic conversations with responses that are selected from a list based on natural language processing.
Study: NCT06506058

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVS and EEG
Description: The participant can choose to participate in one or more of the following experiments. (Any two of these visits will be separated by at least one week.) Experiment 1: EVS during gait initiation (forward stepping, 2 visits) Experiment 2: EVS during turning (1 visit) Experiment 3: EEG during gait initiation (forward stepping, 1 visit) Experiment 4: EEG during RAMS (1 visit)~vestibular activity will be assessed using the noninvasive neuromodulation technique of electrical vestibular stimulation (EVS, Experiments 1 and 2) and cortical activity will be assessed by recording via electroencephalography (EEG, Experiments 3 and 4, no stimulation included).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVS and EEG
Description: The participant can choose to participate in one or more of the following experiments. (Any two of these visits will be separated by at least one week.) Experiment 1: EVS during gait initiation (forward stepping, 2 visits) Experiment 2: EVS during turning (1 visit) Experiment 3: EEG during gait initiation (forward stepping, 1 visit) Experiment 4: EEG during RAMS (1 visit)~vestibular activity will be assessed using the noninvasive neuromodulation technique of electrical vestibular stimulation (EVS, Experiments 1 and 2) and cortical activity will be assessed by recording via electroencephalography (EEG, Experiments 3 and 4, no stimulation included).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVS and EEG
Description: The participant can choose to participate in one or more of the following experiments. (Any two of these visits will be separated by at least one week.) Experiment 1: EVS during gait initiation (forward stepping, 2 visits) Experiment 2: EVS during turning (1 visit) Experiment 3: EEG during gait initiation (forward stepping, 1 visit) Experiment 4: EEG during RAMS (1 visit)~vestibular activity will be assessed using the noninvasive neuromodulation technique of electrical vestibular stimulation (EVS, Experiments 1 and 2) and cortical activity will be assessed by recording via electroencephalography (EEG, Experiments 3 and 4, no stimulation included).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVS and EEG
Description: The participant can choose to participate in one or more of the following experiments. (Any two of these visits will be separated by at least one week.) Experiment 1: EVS during gait initiation (forward stepping, 2 visits) Experiment 2: EVS during turning (1 visit) Experiment 3: EEG during gait initiation (forward stepping, 1 visit) Experiment 4: EEG during RAMS (1 visit)~vestibular activity will be assessed using the noninvasive neuromodulation technique of electrical vestibular stimulation (EVS, Experiments 1 and 2) and cortical activity will be assessed by recording via electroencephalography (EEG, Experiments 3 and 4, no stimulation included).
Study: NCT05641428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARI-0001
Description: Infusion with a single target dose of 2.0 x 10\^6 Point of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axi-cel
Description: Infusion with a single target dose of 2.0 x 10\^6 Standard of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
Study: NCT04311996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TSST
Description: Participants will, via an online session, complete the TSST which is a standardized speech \& math performance known to elicit a cortisol stress response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TSST
Description: Participants will, via an online session, complete the TSST which is a standardized speech \& math performance known to elicit a cortisol stress response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TSST
Description: Participants will, via an online session, complete the TSST which is a standardized speech \& math performance known to elicit a cortisol stress response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TSST
Description: Participants will, via an online session, complete the TSST which is a standardized speech \& math performance known to elicit a cortisol stress response.
Study: NCT05640479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 hours
Study: NCT05575167

Intervention type: DRUG
Intervention: Zoledronate or Alendronate
Description: infusion (for zoledronate) or oral digestion (for alendronate)

Intervention type: DRUG
Intervention: Zoledronate or Alendronate
Description: infusion (for zoledronate) or oral digestion (for alendronate)

Intervention type: DRUG
Intervention: Zoledronate or Alendronate
Description: infusion (for zoledronate) or oral digestion (for alendronate)
Study: NCT05609045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized COVID-19 mRNA Vaccine
Description: RH109 is a mRNA-based vaccine encoding the N-Terminal Domain (NTD) - Receptor Binding Domain (RBD) derived from Spike (S) protein of SARS-CoV-2 Omicron variant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: 0.9% sodium chloride
Study: NCT05640479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive dexmedetomidine after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h
Study: NCT06473766

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RF data extraction
Description: To will be acquired:~10 S-Harmonic images (5 in longitudinal plane, 5 in orthogonal plane), 10 B-mode fundamental images (without Harmonic), 1 gray-scale video clip, 1 gray-scale 3D vol will be stored in Harmonic settings and RF-preset.~The Region of interest (ROI) of each image will be manually segmented by a trained gynecologist using the software Aliza version 1.48. The ROI will include only the solid component of the mass. Additional analysis will be performed by using a predefined ROI (area 2x2 cm2). Radiomic features will be extracted using the MODDICOM, an open-source in-house software solution developed by the Knowledge Based Oncology Labs (Rome, Italy) for quantitative imaging analysis fully compliant with the Image Biomarker Standardization Initiative recommendations. The features will be considered: intensity-based statistical and textural.
Study: NCT04528654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health Application
Description: The participants will be given instructions to use their smartphone or tablet to download the hypertension tracking app. They will follow the instructions provided within the app and use it to track their blood pressure over the next six months.
Study: NCT05402592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbonhydrate rich drink
Description: It will be prepared by adding 50 g of carbohydrates to 1200 ml of water in total and will be given to the patients the night before the surgery and the morning of the surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: A total of 1200 ml of water will be given to the patients the night before and the morning of the surgery.
Study: NCT06049745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 Microgram Oral Tablet
Description: S.L misoprostol 400 mcg
Study: NCT06120816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric Oxide Releasing Mouthwash will be self-administered by the participant three times throughout the day for 21 days. The intervention solution will be poured into their mouth from a medication cup containing 20 mL of the solution. Total exposure to study intervention will be a maximum of 63 treatments totaling 1,260 mL. All participants will be monitored for 7 days post-last treatment dose (to Day 28).
Study: NCT06244225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib； Sintilimab； HAIC
Description: Drug: Sintilimab Q3W 200mg IV d1, Q3W~Drug: Donafenib 200 mg BID d1-21, Q3W~other: HAIC Q3W Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.
Study: NCT06031454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leritrelvir
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leritrelvir
Description: oral
Study: NCT06293807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine 2 % with 1:100,000 epinephrine
Description: Local anesthetic used during dental procedures

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine 0.5% with 1:200,000 epinephrine
Description: Local anesthetic used during dental procedures

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline solution used in place of local anesthetic
Study: NCT05248945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive a single dose of film-coated evobrutinib tablet (TF2) on Day 1 and Day 19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Participants will receive carbamazepine tablet twice daily from Days 2 to 25.
Study: NCT06065033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients will perform 5 days of supervised stationary cycling exercise (with EKG telemetry) per week over a period of 4 weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR).~* Of the 5 sessions, 3 will be HIIT sessions and 2 will be MOD sessions.~* Subjects exercising on the HIIT day will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~* Subjects exercising on the MOD days will perform uninterrupted for 40 minutes duration at 60-65% of PHR progressing to 40 minutes duration at 70-75% of PHR by the end of week 2.~* Each training session will begin with a 10-min warm-up at 50% PHR and end with a 5-min cool down at 50% PHR. Exercise progression may have to be modified according to individual subject exercise tolerance.
Study: NCT05461677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAIRE smart walker
Description: Participants will walk along the 10-meter walkway 5 times using the SAIRE smart walker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard 4-wheeled walker
Description: Participants will walk along the 10-meter walkway 5 times using a standard 4-wheeled walker
Study: NCT06559163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obexelimab
Description: Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRllb, resulting in down regulation of B cell activity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04801368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomization of two local anesthetics.
Description: Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomization of two local anesthetics.
Description: Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
Study: NCT05461677

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No walking aid
Description: Participants will walk along the 10-meter walkway 5 times without using a walking aid
Study: NCT05871151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: Trans-auricular Vagus Nerve Stimulation is a non-invasive method of stimulating the auricular branch of the vagus nerve through the inner ear. Trans-auricular Vagus Nerve Stimulation will be provided using a commercially available device. The investigators will use custom earbuds that will make the experience significantly more comfortable than traditional transauricular Vagus Nerve Stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: All participants will be guided through exercises led by a trained exercise specialist, and will include: 1) intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations. The exercise intervention proposed involves the supervision of a licensed PT at all times during the treatment session. Exercise will be provided in a clinical setting, 45 minutes per session, up to 3 sessions/week, for 4-6 weeks total.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: All participants will be guided through exercises led by a trained exercise specialist, and will include: 1) intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations. The exercise intervention proposed involves the supervision of a licensed PT at all times during the treatment session. Exercise will be provided in a clinical setting, 45 minutes per session, up to 3 sessions/week, for 4-6 weeks total.
Study: NCT06040099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous)
Study: NCT05778825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Minoxidil
Description: minoxidil at a dose of 0.01 (\<40kg) and 0.02 (≥40kg) mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Minoxidil
Description: minoxidil at a dose of 0.01 (\<40kg) and 0.02 (≥40kg) mg/kg/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo for 4 months
Study: NCT05749445

Intervention type: DRUG
Intervention: Nirmatrelvir-Ritonavir
Description: Nirmatrelvir-Ritonavir